The aim of the visit was to highlight the company’s commitment to innovation, development and the added value within the Valencian Community (Spain).
The pharmaceutical company from Alicante (Spain), Asac Pharmaceutical Inmunology, S.A., (API), belonging to Asacpharma group, and the only biotechnological laboratory authorised to manufacture biological medicines for human use in the Valencian Community, has received the visit of the Minister of Sustainable Economy, Rafael Climent González, and the General Director of IVACE, Júlia Company Sanus, at its production plant, with the aim of presenting the new facilities and its production model.
Accompanied by the CEO, Eliseo Aller Miró, and the Technical Director, Flavia Hernández, they visited the new facilities, and highlighted the economic investment recently made in the production plant, as a clear example of its commitment to the business model that values R&D&i in the Valencian Community.
This investment has made it possible to improve, optimise and implement new processes, as well as to improve the laboratory’s production capacity. The manufacturing plant currently employs more than 35 people, generating stable and highly qualified jobs, generating wealth and value within the Valencian Community.
API, with more than 30 years of uninterrupted activity, is a reference in the manufacture of diagnostics and individualised sublingual allergen immunotherapy treatments both nationally and internationally. Likewise, the investment recently made has led to the incorporation of the process of manufacturing autovaccines from biological samples from patients.
It is worth to remark the important international work carried out by the company throughout its history, extending its presence to the 5 continents. API is present in Latin America through its subsidiaries, including IPI ASAC do Brasil and ASAC Pharma Mexico, where it has a leading position.
On the other hand, it exports to international markets, both European and Asian, where it is continuously diversifying thanks to the international partners. Currently, more than 70% of the Asacpharma Group’s turnover is generated outside Spain.
